ATM-AVI

Phase 2Small molecule

Pfizer

ATM-AVI is one of 10 small molecule programs targeting Gram-Negative Bacterial Infections. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gram-Negative Bacterial InfectionsRecruiting

Gram-Negative Bacterial InfectionsPhase 2

Recruiting

Competition

Competitive Landscape

18 competitors in Gram-Negative Bacterial Infections

#DrugCompanyPhaseTrials

Fetroja

Shionogi

Approved

1 2

Avycaz

PPhiladelphia Eye Associates

Approved

—3

Ceftazidime-Avibactam

Pfizer

Approved

1 4

Tygacil

PPrism Pharmaceuticals

Approved

—5

Merrem

BB. Braun Medical Inc.

Approved

—6

Ceftolozane-Tazobactam

TTemple University

Approved

1 7

Meropenem-Vaborbactam

MMelinta Therapeutics, Inc.

Approved

1 8

Primaxin

Minocin

ATM-AVI

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Gram-Negative Bacterial Infections

NCT05639647

Clinical

Trials by Indication[1]

Infections1 trial

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

Completed· Pfizer logo

Pfizer·Phase 3·NCT03329092·422 enrolled

Treatment1 trial

Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE)

Completed· Pfizer logo

Pfizer·Phase 2·NCT02655419·40 enrolled

Gram-Negative Bacterial Infections1 trial

A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTION

Recruiting· Pfizer logo

Pfizer·Phase 2·NCT05639647·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ATM-AVI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATM-AVI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATM-AVI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

ATM-AVI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Infections1 trial

Treatment1 trial

Gram-Negative Bacterial Infections1 trial

References

Drug Info

Quick Facts

Related News